Class Action Notice for Gossamer Bio Investors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy GOSS?
Source: Globenewswire
- Class Action Initiated: The Portnoy Law Firm has launched a class action on behalf of investors who purchased Gossamer Bio securities between June 16, 2025, and February 20, 2026, with a deadline of June 1, 2026, for filing a lead plaintiff motion to protect their legal rights.
- False Information Disclosure: During the class period, Gossamer's management provided investors with positive information regarding its Phase 3 PROSERA study while concealing significant adverse facts about the study design, leading investors to purchase securities at artificially inflated prices.
- Study Results Failure: On February 23, 2026, Gossamer announced that its Phase 3 PROSERA study failed to meet its primary endpoint, achieving only a +13.3 meter placebo-adjusted gain in six-minute walk distance (6MWD), which did not meet the required 0.025 alpha threshold, causing the stock price to plummet over 80% in a single day.
- Legal Recourse: The Portnoy Law Firm offers complimentary case evaluations for affected investors, aiming to assist them in recovering losses due to corporate wrongdoing, with the founding partner having recovered over $5.5 billion for aggrieved investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GOSS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GOSS
Wall Street analysts forecast GOSS stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.432
Low
10.00
Averages
12.33
High
15.00
Current: 0.432
Low
10.00
Averages
12.33
High
15.00
About GOSS
Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Class Action Notice for Gossamer Bio Investors
- Class Action Initiated: The Portnoy Law Firm has launched a class action on behalf of investors who purchased Gossamer Bio securities between June 16, 2025, and February 20, 2026, with a deadline of June 1, 2026, for filing a lead plaintiff motion to protect their legal rights.
- False Information Disclosure: During the class period, Gossamer's management provided investors with positive information regarding its Phase 3 PROSERA study while concealing significant adverse facts about the study design, leading investors to purchase securities at artificially inflated prices.
- Study Results Failure: On February 23, 2026, Gossamer announced that its Phase 3 PROSERA study failed to meet its primary endpoint, achieving only a +13.3 meter placebo-adjusted gain in six-minute walk distance (6MWD), which did not meet the required 0.025 alpha threshold, causing the stock price to plummet over 80% in a single day.
- Legal Recourse: The Portnoy Law Firm offers complimentary case evaluations for affected investors, aiming to assist them in recovering losses due to corporate wrongdoing, with the founding partner having recovered over $5.5 billion for aggrieved investors.
See More
Gossamer Bio Faces Class Action Lawsuit
- Class Action Initiated: Berger Montague PC has announced a class action lawsuit against Gossamer Bio on behalf of investors who purchased shares between June 16, 2025, and February 20, 2026, reflecting significant investor dissatisfaction with the company's performance.
- Stock Price Plunge: Following the February 23, 2026 announcement that Gossamer's Phase 3 trial for seralutinib failed to meet its primary endpoint, the company's shares plummeted over 80% in a single day, resulting in substantial losses for investors.
- Investor Rights: Investors must apply by June 1, 2026, to be appointed as lead plaintiff representatives in the class action, indicating a heightened concern over the company's future legal actions, which could impact its reputation and future financing capabilities.
- Legal Firm Background: Berger Montague is a leading law firm specializing in complex civil litigation and class actions, having recovered over $50 billion for clients over the past 55 years, showcasing its strong capabilities and influence in the legal field.
See More
Gossamer Bio Investors Reminder for Class Action Filing
- Filing Deadline: Investors in Gossamer Bio must file a lead plaintiff motion by June 1, 2026, to participate in the class action lawsuit concerning securities purchased between June 16, 2025, and February 20, 2026, reflecting strong investor response to the company's performance failure.
- Study Failure Announcement: On February 23, 2026, Gossamer disclosed that its Phase 3 PROSERA study for pulmonary arterial hypertension failed to meet its primary endpoint, resulting in an 80.3% stock price drop to $0.42 per share, indicating a severe loss of investor confidence in the company's future prospects.
- Allegations of Misrepresentation: The lawsuit alleges that throughout the class period, the company made materially false and misleading statements and failed to disclose the heavily treated lower-risk patient population in Latin America, which contributed to the poor study results and exacerbated investor losses.
- Investor Rights Protection: Investors who purchased Gossamer securities during the class period may apply to be lead plaintiffs before the deadline to recover losses due to the company's misleading statements, highlighting the legal system's role in protecting investor rights.
See More
Class Action Filed Against Gossamer Bio for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Gossamer Bio, aiming to recover damages for investors who purchased securities between June 16, 2025, and February 20, 2026, indicating significant legal risks for the company.
- Allegations of False Statements: The complaint alleges that Gossamer Bio concealed critical adverse facts regarding inadequate placebo control in its Phase 3 PROSERA study while promoting positive results, leading to artificially inflated stock prices.
- Investor Losses: Due to these false statements, investors purchased Gossamer shares at inflated prices, potentially incurring substantial financial losses, highlighting deficiencies in corporate governance and transparency.
- Commitment to Legal Support: Bronstein, Gewirtz & Grossman, LLC emphasizes its contingency fee arrangement, ensuring that investors will only incur costs if the lawsuit is successful, reflecting a strong commitment to protecting investor rights.
See More
Gossamer Bio Faces Class Action Lawsuit Over Misleading Statements
- Class Action Filed: Wolf Haldenstein Adler Freeman & Herz LLP has announced a class action lawsuit on behalf of shareholders who purchased Gossamer Bio securities between June 16, 2025, and February 20, 2026, with a deadline of June 1, 2026, for investors to apply as lead plaintiffs.
- Allegations of Misrepresentation: The complaint alleges that throughout the class period, defendants made materially false and misleading statements and failed to disclose adverse facts about the company's business and operations, resulting in significant investor losses.
- Clinical Trial Failure: On February 23, 2026, Gossamer disclosed that its Phase 3 PROSERA study of seralutinib for pulmonary arterial hypertension failed to meet its primary endpoint, as patients at Latin American sites performed well on placebo due to the enrollment of a heavily-treated lower-risk population.
- Stock Price Collapse: Following the announcement of the study results, Gossamer's stock price plummeted by $1.71, or 80.3%, closing at $0.42 per share, indicating severe market pessimism regarding the company's future prospects.
See More
Gossamer Bio Faces Securities Litigation Investigation
- Litigation Investigation Launched: Faruqi & Faruqi, LLP is investigating potential claims against Gossamer Bio, Inc., specifically for investors who purchased securities between June 16, 2025, and February 20, 2026, urging them to seek lead plaintiff status by the June 1, 2026 deadline.
- Clinical Trial Failure: On February 23, 2026, Gossamer Bio revealed adverse topline results from its Phase 3 PROSERA study, failing to meet the primary endpoint of improving six-minute walk distance at Week 24, with a placebo-adjusted gain of +13.3 meters that did not achieve statistical significance, leading to a loss of investor confidence.
- Stock Price Plummets: Following the trial results announcement, Gossamer's stock price collapsed from $2.13 per share on February 20, 2026, to $0.42 per share, representing a decline of over 80% in a single trading day, reflecting extreme pessimism about the company's future.
- Legal Rights Reminder: Faruqi & Faruqi encourages anyone with information regarding Gossamer's conduct, including whistleblowers and former employees, to contact the firm directly to assist in potential class action litigation, ensuring that investors' legal rights are protected.
See More
Class Action Notice for Gossamer Bio Investors
- Class Action Initiated: The Portnoy Law Firm has launched a class action on behalf of investors who purchased Gossamer Bio securities between June 16, 2025, and February 20, 2026, with a deadline of June 1, 2026, for filing a lead plaintiff motion to protect their legal rights.
- False Information Disclosure: During the class period, Gossamer's management provided investors with positive information regarding its Phase 3 PROSERA study while concealing significant adverse facts about the study design, leading investors to purchase securities at artificially inflated prices.
- Study Results Failure: On February 23, 2026, Gossamer announced that its Phase 3 PROSERA study failed to meet its primary endpoint, achieving only a +13.3 meter placebo-adjusted gain in six-minute walk distance (6MWD), which did not meet the required 0.025 alpha threshold, causing the stock price to plummet over 80% in a single day.
- Legal Recourse: The Portnoy Law Firm offers complimentary case evaluations for affected investors, aiming to assist them in recovering losses due to corporate wrongdoing, with the founding partner having recovered over $5.5 billion for aggrieved investors.
See More
Gossamer Bio Faces Class Action Lawsuit
- Class Action Initiated: Berger Montague PC has announced a class action lawsuit against Gossamer Bio on behalf of investors who purchased shares between June 16, 2025, and February 20, 2026, reflecting significant investor dissatisfaction with the company's performance.
- Stock Price Plunge: Following the February 23, 2026 announcement that Gossamer's Phase 3 trial for seralutinib failed to meet its primary endpoint, the company's shares plummeted over 80% in a single day, resulting in substantial losses for investors.
- Investor Rights: Investors must apply by June 1, 2026, to be appointed as lead plaintiff representatives in the class action, indicating a heightened concern over the company's future legal actions, which could impact its reputation and future financing capabilities.
- Legal Firm Background: Berger Montague is a leading law firm specializing in complex civil litigation and class actions, having recovered over $50 billion for clients over the past 55 years, showcasing its strong capabilities and influence in the legal field.
See More
Gossamer Bio Investors Reminder for Class Action Filing
- Filing Deadline: Investors in Gossamer Bio must file a lead plaintiff motion by June 1, 2026, to participate in the class action lawsuit concerning securities purchased between June 16, 2025, and February 20, 2026, reflecting strong investor response to the company's performance failure.
- Study Failure Announcement: On February 23, 2026, Gossamer disclosed that its Phase 3 PROSERA study for pulmonary arterial hypertension failed to meet its primary endpoint, resulting in an 80.3% stock price drop to $0.42 per share, indicating a severe loss of investor confidence in the company's future prospects.
- Allegations of Misrepresentation: The lawsuit alleges that throughout the class period, the company made materially false and misleading statements and failed to disclose the heavily treated lower-risk patient population in Latin America, which contributed to the poor study results and exacerbated investor losses.
- Investor Rights Protection: Investors who purchased Gossamer securities during the class period may apply to be lead plaintiffs before the deadline to recover losses due to the company's misleading statements, highlighting the legal system's role in protecting investor rights.
See More
Class Action Filed Against Gossamer Bio for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Gossamer Bio, aiming to recover damages for investors who purchased securities between June 16, 2025, and February 20, 2026, indicating significant legal risks for the company.
- Allegations of False Statements: The complaint alleges that Gossamer Bio concealed critical adverse facts regarding inadequate placebo control in its Phase 3 PROSERA study while promoting positive results, leading to artificially inflated stock prices.
- Investor Losses: Due to these false statements, investors purchased Gossamer shares at inflated prices, potentially incurring substantial financial losses, highlighting deficiencies in corporate governance and transparency.
- Commitment to Legal Support: Bronstein, Gewirtz & Grossman, LLC emphasizes its contingency fee arrangement, ensuring that investors will only incur costs if the lawsuit is successful, reflecting a strong commitment to protecting investor rights.
See More
Gossamer Bio Faces Class Action Lawsuit Over Misleading Statements
- Class Action Filed: Wolf Haldenstein Adler Freeman & Herz LLP has announced a class action lawsuit on behalf of shareholders who purchased Gossamer Bio securities between June 16, 2025, and February 20, 2026, with a deadline of June 1, 2026, for investors to apply as lead plaintiffs.
- Allegations of Misrepresentation: The complaint alleges that throughout the class period, defendants made materially false and misleading statements and failed to disclose adverse facts about the company's business and operations, resulting in significant investor losses.
- Clinical Trial Failure: On February 23, 2026, Gossamer disclosed that its Phase 3 PROSERA study of seralutinib for pulmonary arterial hypertension failed to meet its primary endpoint, as patients at Latin American sites performed well on placebo due to the enrollment of a heavily-treated lower-risk population.
- Stock Price Collapse: Following the announcement of the study results, Gossamer's stock price plummeted by $1.71, or 80.3%, closing at $0.42 per share, indicating severe market pessimism regarding the company's future prospects.
See More
Gossamer Bio Faces Securities Litigation Investigation
- Litigation Investigation Launched: Faruqi & Faruqi, LLP is investigating potential claims against Gossamer Bio, Inc., specifically for investors who purchased securities between June 16, 2025, and February 20, 2026, urging them to seek lead plaintiff status by the June 1, 2026 deadline.
- Clinical Trial Failure: On February 23, 2026, Gossamer Bio revealed adverse topline results from its Phase 3 PROSERA study, failing to meet the primary endpoint of improving six-minute walk distance at Week 24, with a placebo-adjusted gain of +13.3 meters that did not achieve statistical significance, leading to a loss of investor confidence.
- Stock Price Plummets: Following the trial results announcement, Gossamer's stock price collapsed from $2.13 per share on February 20, 2026, to $0.42 per share, representing a decline of over 80% in a single trading day, reflecting extreme pessimism about the company's future.
- Legal Rights Reminder: Faruqi & Faruqi encourages anyone with information regarding Gossamer's conduct, including whistleblowers and former employees, to contact the firm directly to assist in potential class action litigation, ensuring that investors' legal rights are protected.
See More
